Recent Blog Posts

View Post: Schering-Plough Announces U.S. Filing of Mometasone Furoate ...
22 Jul 2009
The fixed-dose combination of mometasone furoate and formoterol fumarate for the treatment of asthma in patients younger than 12 years of age and for use in COPD is currently in Phase III development. Schering-Plough is an innovation- ...
View Blog: Latest Medical Technology from Bio-Medicine.Org - http://www.bio-medicine.org/medicine-technology-1/

---

View Post: NPCi Blog: Addition of inhaled budesonide/formoterol to tiotropium ...
5 Nov 2009
This NPCi blog discusses the findings of a short-term RCT that claims benefits for the addition of inhaled budesonide/formoterol to tiotropium (i.e. triple vs. single therapy) in patients with COPD. The 12-week, study involved 660 ...
View Blog: NeLM - News - http://www.nelm.nhs.uk/en/NeLM-Area/News/

---

View Post: New analysis shows SYMBICORT® improved airflow obstruction in ...
9 Nov 2009
SYMBICORT 160/4.5 mcg is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ... is a combination of two proven respiratory medications – budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA). SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of COPD or asthma. ...
View Blog: AZ US news feed - http://www.astrazeneca-us.com/

---

View Post: Triple versus single therapy in COPD « NPCi blog
4 Nov 2009 by bowersc  
A short-term randomised controlled trial claims benefits for the addition of inhaled budesonide/formoterol to tiotropium (i.e. triple vs. single therapy) in patients with COPD. However, limitations of the study question its validity and ...
View Blog: NPCi blog - http://www.npci.org.uk/blog/

---

View Post: Mainstay of the Global Workforce - 40-65 Year Olds - Hit Hardest ...
17 Nov 2009 by Education For Health  
May 20th, 2009 BASEL, Switzerland - **This press release is not intended for the UK media** - Once daily QAB149 (indacaterol) significantly improves lung function compared to formoterol and tiotropium, two currently approved COPD ...
View Blog: PR Hub - http://blog.taragana.com/pr/

---

View Post: Triple therapy halves exacerbations in moderate-to-severe COPD ...
8 Oct 2009 by admin  
“This is the first clinical study to directly evaluate the clinical efficacy of combining budesonide/formoterol with tiotropium in patients with COPD,” said Dr. Welte. “This treatment approach was associated with marked improvements in ...
View Blog: BreakThrough Digest Medical News - http://www.breakthroughdigest.com/

---

View Post: FDA OKs Asthma Drug for COPD
2 Mar 2009
In the clinical trials, COPD patients taking Symbicort had a greater improvement in their lung function, compared to patients using a placebo, formoterol, or budesonide. It typically took five minutes for lung function to start to ...
View Blog: WebMD Health News Center - The latest breaking... - http://www.webmd.com/

---

View Post: FDA accepts NDA for mometasone furoate/formoterol fumarate ...
23 Jul 2009
August 19, 2009. Forest Laboratories and Glenmark Pharmaceuticals announced top-line results from a Phase 2b dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). ...
View Blog: Latest articles from MPR - http://www.empr.com/

---

View Post: Perforomist Inhalation Solution Data Presented At American ...
28 Oct 2009 by admin  
Data from two presentations highlighting the use of Perforomist® (formoterol fumarate) Inhalation Solution in moderate to severe chronic obstructive pulmonary disease (COPD) patients were featured at the International Conference of the ...
View Blog: Discuss Pharmacy - http://discusspharmacy.com/

---